Nephrogen

About Nephrogen

Nephrogen is a preclinical biotech company focused on developing curative genomic medicines for serious diseases, with an initial emphasis on kidney and pancreatic disorders. The company aims to overcome delivery challenges in genomic therapy to enable lasting treatments for these tissues. Its NeFIND platform uses high-throughput in vivo screening to engineer novel gene delivery vectors that are more efficient and less immunogenic. Nephrogen is a Stanford/Harvard spin-out founded by leaders in computational biology, nephrology, and genetics.